Updates from Berlin: New Developments in Huntington’s Disease

I never see any updates on stroke from any medical forum/association. Because there are none? Stroke needs nothing fixed?

Updates from Berlin:New Developments in Huntington’s Disease

Release Date: July 15, 2016
Expiration Date: July 14, 2017
By clicking "Continue to Activity" you attest that you have read and understood the CME required elements. Continue to Activity

Estimated Time to Complete

45 minutes

Activity Overview

Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system (CNS) characterized by abnormal involuntary movements, behavioral disturbance, cognitive dysfunction, and psychiatric disease. Currently, there is no established treatment to delay the onset or prevent the progression of HD, and available pharmacologic interventions for controlling the motor and non-motor aspects of the disease are limited. However, recent therapeutic advances, particularly in suppressing chorea, have been shown to have a favorable effect on motor function, safety, and quality of life. In this roundtable discussion, recorded immediately after the 2016 International Congress of Parkinson's Disease and Movement Disorders Meeting in Berlin, Germany, leading experts in HD explore some of the most recent evidence and latest developments in the treatment for this devastating disease.

Providership

This continuing medical education activity is provided
by  

Support Acknowledgement

This activity is supported by an educational grant from Teva Pharmaceuticals.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Review the latest data of the use of predictive testing and biomarkers in patients who are carriers of the mutant Htt gene variant prior to conversion to manifest HD.
• Evaluate the latest clinical data regarding the mechanism of action, efficacy, and safety of available and emerging agents for the management of chorea and other symptoms associated with HD.
• Assess the utilization of emerging agents in the management of patients with HD.

Target Audience

The intended audience for the activity is neurologists, psychiatrists, and other health care professionals involved in the treatment of patients with HD.